These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 23040257)

  • 21. [Metastases from urothelial carcinoma : future and prospects].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S277-84. PubMed ID: 19070804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic chemotherapy in locally advanced and/or metastatic bladder cancer.
    Pectasides D; Pectasides M; Economopoulos T
    Cancer Treat Rev; 2006 Oct; 32(6):456-70. PubMed ID: 16935429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
    Dreicer R; Roth B; Wilding G;
    Cancer; 2003 Apr; 97(8 Suppl):2109-14. PubMed ID: 12673703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer.
    Raghavan D
    Cancer; 2003 Apr; 97(8 Suppl):2083-9. PubMed ID: 12673700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging drugs for urothelial (bladder) cancer.
    Cumberbatch K; He T; Thorogood Z; Gartrell BA
    Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
    McCaffrey JA; Herr HW
    Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging targeted therapies for bladder cancer: a disease waiting for a drug.
    Dovedi SJ; Davies BR
    Cancer Metastasis Rev; 2009 Dec; 28(3-4):355-67. PubMed ID: 19997963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical applications for targeted therapy in bladder cancer.
    Adam L; Kassouf W; Dinney CP
    Urol Clin North Am; 2005 May; 32(2):239-46, vii. PubMed ID: 15862621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of trials using chemotherapy for metastatic bladder cancer.
    Tannock IF
    Prog Clin Biol Res; 1988; 260():487-98. PubMed ID: 3283769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular genetics of bladder cancer: targets for diagnosis and therapy.
    Baffa R; Letko J; McClung C; LeNoir J; Vecchione A; Gomella LG
    J Exp Clin Cancer Res; 2006 Jun; 25(2):145-60. PubMed ID: 16918124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined chemotherapy and irradiation for transitional cell cancer of the bladder: a review.
    Beuzeboc P; Pontvert D; Pouillart P; Cosset JM
    J Infus Chemother; 1995; 5(4):218-20. PubMed ID: 8934733
    [No Abstract]   [Full Text] [Related]  

  • 32. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder?
    Sweeney P; Millikan R; Donat M; Wood CG; Radtke AS; Pettaway CA; Grossman HB; Dinney CP; Swanson DA; Pisters LL
    J Urol; 2003 Jun; 169(6):2113-7. PubMed ID: 12771730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Signaling Transduction Pathways in Bladder Cancer.
    Abbosh PH; McConkey DJ; Plimack ER
    Curr Oncol Rep; 2015 Dec; 17(12):58. PubMed ID: 26472299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of advanced bladder cancer in the era of targeted therapies.
    Soave A; Engel O; Von Amsberg G; Becker A; Dahlem R; Shariat SF; Fisch M; Rink M
    Minerva Urol Nefrol; 2015 Jun; 67(2):103-15. PubMed ID: 25604695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytohistologic correlation of urothelial lesions secondary to photodynamic therapy.
    Broghamer WL; Parker JE; Harty JI; Gilkey CM
    Acta Cytol; 1989; 33(6):881-6. PubMed ID: 2531527
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel therapeutic targets in advanced urothelial carcinoma.
    Rouanne M; Loriot Y; Lebret T; Soria JC
    Crit Rev Oncol Hematol; 2016 Feb; 98():106-15. PubMed ID: 26589398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-ErbB targeted therapy and urothelial tumors].
    Amsellem-Ouazana D; Goldwasser F; Bieche I; Lidereau R; Zerbib M
    Prog Urol; 2005 Dec; 15(6 Suppl 1):1229-35. PubMed ID: 16734210
    [No Abstract]   [Full Text] [Related]  

  • 39. Bladder carcinoma: understanding advanced and metastatic disease with potential molecular therapeutic targets.
    Ahmed HU; Arya M; Patel HR
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1011-22. PubMed ID: 16336092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significant activity of single agent vinorelbine against small-cell cancer of the bladder as second line chemotherapy: a case series and review of the literature.
    June RR; Dougherty DW; Reese CT; Harpster LE; Hoffman SL; Drabick JJ
    Urol Oncol; 2012; 30(2):192-5. PubMed ID: 20363163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.